Surface modification engineering of two-dimensional titanium carbide for efficient synergistic multitherapy of breast cancer

2020 ◽  
Vol 8 (30) ◽  
pp. 6402-6417 ◽  
Author(s):  
Lei Bai ◽  
Wenhui Yi ◽  
Taiyang Sun ◽  
Yilong Tian ◽  
Ping Zhang ◽  
...  

A nanocomposite drug delivery system (Ti3C2@Met@CP) can be used for the synergistic treatment of tumors through photothermal/photodynamic/chemotherapy and can also inhibit tumor recurrence and metastasis by activating the immune system.

2021 ◽  
Vol 45 (6) ◽  
pp. 3079-3087
Author(s):  
Yue Xu ◽  
Mingming Yang ◽  
Qiyue Ma ◽  
Xiang Di ◽  
Guolin Wu

A nano-injectable hydrogel with fluorescence properties and controlled sequential release of dual drugs.


2018 ◽  
Vol 51 (5) ◽  
pp. e12488 ◽  
Author(s):  
Tingting Kong ◽  
Liying Hao ◽  
Yuanyuan Wei ◽  
Xiaoxiao Cai ◽  
Bofeng Zhu

2020 ◽  
Vol Volume 15 ◽  
pp. 5217-5226 ◽  
Author(s):  
Chen Jianxian ◽  
Kalsoom Saleem ◽  
Muhammad Ijaz ◽  
Masood Ur-Rehman ◽  
Ghulam Murtaza ◽  
...  

2020 ◽  
Vol 8 (16) ◽  
pp. 3527-3533 ◽  
Author(s):  
Lairong Ding ◽  
Junwei Li ◽  
Changrong Wu ◽  
Feng Yan ◽  
Xuemei Li ◽  
...  

A novel RNA-triple-helix hydrogel for treatment of triple negative breast cancers (TNBCs) by incorporating RNA-triple-helix and siRNA duplexes of CXCR4 into the same RNA nanoparticles was developed, without the synthetic polycationic reagents.


Nanomedicine ◽  
2020 ◽  
Vol 15 (10) ◽  
pp. 981-1000
Author(s):  
C Ethan Byrne ◽  
Carlos E Astete ◽  
Manibarathi Vaithiyanathan ◽  
Adam T Melvin ◽  
Mahsa Moradipour ◽  
...  

Aim: Few targeted therapies are available for triple-negative breast cancer (TNBC) patients. Here, we propose a novel alkaline-lignin-conjugated-poly(lactic- co-glycolic acid) (L-PLGA) nanoparticle drug delivery system to improve the efficacy of targeted therapies. Materials & methods: L-PLGA nanoparticles (NPs) loaded with the MEK1/2 inhibitor GDC-0623 were characterized, tested in vitro on MDA-MB-231 TNBC cell line and compared with loaded PLGA NPs. Results: Loaded L-PLGA NPs were less than half the size of PLGA NPs, had slower drug release and improved the efficacy of GDC-0623 when tested in vitro. We demonstrated that GDC-0623 reversed epithelial-to-mesenchymal transition in TNBC. Conclusion: Our findings indicate that L-PLGA NPs are superior to PLGA NPs in delivering GDC-0623 to cancer cells for improved efficacy in vitro.


Sign in / Sign up

Export Citation Format

Share Document